News

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

In celebration of Ophthalmology Times' 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the past 5 decades.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic retinopathy compared to telemedicine evaluations.

Fundus images of diabetic retinopathy were assessed by general ophthalmologists, retina specialists and the Aireen artificial intelligence system

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Tertiary syphilis, which can develop years to decades after the initial infection, is characterized by chronic inflammatory damage affecting multiple organ systems.

Treatment regimens with long-duration therapies continue to be a conversation starter among retina specialists

The Congress on Controversies in Ophthalmology highlights debates, but also discussions

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic retinopathy compared to telemedicine evaluations.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Recent estimates show that there are over 2 billion users on Instagram, of which over 726.8 million interact with reels on the platform.

Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in patients with open-angle glaucoma.

Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

The ZAP-X system is described by researchers as a "dedicated, self-contained, and self-shielded surgical robot" designed for performing stereotactic surgery (SRS) on the brain, head, and neck. This technology was utilized to treat a patient with uveal melanoma.

Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

Andrew G. Lee, MD, and Drew Carey, MD, return for this episode of 'NeuroOp Guru' to discuss how sixth nerve palsy with chemosis warrants suspicion for a cavernous carotid fistula, emphasizing careful examination for dilated conjunctival vessels and the need for imaging for accurate diagnosis and timely intervention.

How studies into myopia management can increase access to vision care

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

A study on the effects of methylphenidate in children with ADHD found that treated children had lower corneal endothelial cell counts compared to untreated children and a control group.

Accelerated changes in the spherical equivalent refraction (SER) and axial length were seen but no changes in the lens power and thickness were seen in pediatric patients.

Multiple myeloma is a rare cancer that originates in white blood cells (plasma cells) that produce antibodies.

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression